Angel Medical Systems Expands its Senior Leadership Team to Accelerate the Commercialization of the Guardian

Contact:
Karla Bardinas
Think Media Communications
karlab@thinkmedianj.com
732.996.9789

FOR IMMEDIATE RELEASE

Angel Medical Systems Expands its Senior Leadership Team to Accelerate the Commercialization of the Guardian

PDF
Eatontown, NJ, May 31, 2019 

Angel Medical Systems, Inc. (AngelMed) welcomes veteran sales executive Victor Ayers to its senior leadership team as the Senior Vice President of Sales and Marketing. Victor’s responsibilities include building and directing the Company’s national sales team, accelerating the commercialization of the Guardian through new partnerships and channels, and developing marketing and business strategies to further fuel expansion. The Guardian is an implantable cardiac monitor and patient alerting system for people who have had prior Acute Coronary Syndromes (ACS), including heart attacks, that received approval by the U.S. Food and Drug Administration in 2018.

“Victor has a passion and proven track record of penetrating markets in the healthcare industry for various companies, building effective teams, and driving revenue. His expertise navigating health care systems and unrelenting energy will provide an invaluable source of leadership to AngelMed. And more importantly, with Victor spearheading commercialization efforts, patients will soon benefit from the Guardian and get peace of mind,” said Dr. David R. Fischell, Chief Executive Officer.

“Victor’s strategic vision and unwavering dedication will help AngelMed deliver the Guardian to market in the fourth quarter of this year. We are thrilled to have him onboard!” added Dave Keenan, Chief Operating Officer.
Ayers brings more than thirty years of sales and leadership experience to AngelMed. He has a diverse and accomplished career building companies and collaborating with healthcare innovators to break into markets, gain market share, and ensure profit performance.

Ayers has played a critical role in many healthcare “firsts” – including leading the launch of TimelinePI, a process intelligence platform for healthcare and relaunch of the Healthimation mobile app for obesity and diabetes self-management and prevention. He also architected an IT services performance-based methodology which is widely used by health systems and has been featured on ABC Network’s Business Now. Ayers’ accomplishments earned him a spot on the ‘Top 25 Most Influential People” in 2006 by Advance for Health Professional magazine.

About the AngelMed Guardian® System

The AngelMed Guardian® System received approval by the U.S. Food and Drug Administration (FDA) in April 2018. It is an implantable cardiac monitor with patient alerting for patients who have had prior Acute Coronary Syndromes (ACS), including myocardial infarctions (heart attacks) or unstable angina and who remain at high risk for recurrent ACS events. The Angel Med Guardian® System is an adjunct to patient recognized symptoms by detecting potential ongoing ACS events, characterized by sustained ST segment changes and alerting the patient to seek medical attention for those events. Approval of the Angel Med Guardian® System by the U.S. FDA was based on preclinical and clinical data, including data derived from the ALERTS Clinical Study that began in 2009. The Guardian device fills an unmet medical need by providing more effective diagnosis of a life-threatening condition when compared to patient symptoms alone.

About Angel Medical Systems, Inc.

Angel Medical Systems, Inc. was founded in 2001 by Drs. Robert, Tim and David Fischell, active serial entrepreneurs and inventors of medical devices. In 1999, the company filed its first of more than 50 issued US patents relating to detecting cardiac events and patient alerting, with the Company’s first human implant occurring in 2005.

Forward Looking Statements

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward- looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the Company’s products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the performance information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events, or otherwise.

All questions should be directed to:
Karla Bardinas
Think Media Communications
karlab@thinkmedianj.com
732.996.9789